Aquaphoril

Quick links to important sections

Aquaphoril

Method of action: Diuretic

Treatment option: Ascites, Hypertension, Renal Failure

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aquaphoril

What is Aquaphoril?

Aquaphoril is a pharmacological agent belonging to the class of loop diuretics. It is primarily utilized in clinical settings to manage fluid retention, also known as edema, which is associated with various underlying medical conditions. By acting on the kidneys, Aquaphoril facilitates the removal of excess salt and water from the body through increased urine production.

Mechanism of Action

The active therapeutic process of Aquaphoril occurs within the thick ascending limb of the loop of Henle in the kidneys. It inhibits the protein system responsible for transporting sodium, potassium, and chloride. By preventing these electrolytes from being reabsorbed into the bloodstream, the medication ensures they remain within the renal tubule, drawing water with them via osmotic pressure to be excreted.

Clinical Applications

Aquaphoril is commonly indicated for the treatment of fluid buildup resulting from systemic health issues, including:

  • Congestive Heart Failure: Helping to reduce the workload on the heart by decreasing total blood volume.
  • Renal Impairment: Assisting the kidneys when they are unable to maintain fluid balance independently.
  • Hepatic Cirrhosis: Addressing the accumulation of fluid in the abdomen or extremities caused by liver dysfunction.
  • Hypertension: In certain cases, it may be used as a secondary measure to manage high blood pressure by reducing the volume of fluid circulating in the vascular system.

Pharmacological Properties

Aquaphoril is characterized by its rapid onset of action, making it suitable for situations where prompt fluid reduction is necessary. It is available in various formulations to accommodate both acute and long-term management strategies. Unlike other classes of diuretics, loop diuretics like Aquaphoril remain effective even in patients with significantly reduced kidney function.

Regulatory References

  1. Diuretics - MeSH
  2. Antihypertensive Agents - MeSH
  3. Sulfonamides - MeSH
  4. Dosage Forms - NIH
  5. Diuretic Mechanism of Action - NIH
  6. Natriuretic Agents - MeSH
  7. Edema (Fluid Retention) - MedlinePlus
  8. High Blood Pressure (Hypertension) - MedlinePlus

What side effects are possible with Aquaphoril?

Possible Side Effects and Safety Information for Aquaphoril (Xipamide)

Official regulatory documents classify the safety profile of Aquaphoril based primarily on its function as a diuretic. The most frequent and essential safety concern involves electrolyte and metabolic disturbances.

Hypokalaemia (low blood potassium levels) is the most commonly documented adverse effect, classified as Very Common (affecting more than 1 in 10 individuals). Common reactions (affecting 1 in 100 to 1 in 10) include Hyponatraemia (low blood sodium levels), Orthostatic Hypotension (low blood pressure upon standing), and increases in serum Creatinine, Urea, and Uric Acid levels. Gastrointestinal issues such as Nausea and Vomiting, along with Headache, are also commonly listed. Effects on lab parameters, such as increased Urea and Creatinine, are typically noted at the start of treatment.

Serious and Rare Adverse Reactions

While rare, the official safety profile documents serious adverse reactions. These include clinically significant conditions like Haemorrhagic Pancreatitis, Acute Interstitial Nephritis (a form of kidney inflammation), and certain Haematological Disorders such as Thrombocytopenia (low platelet count).

Safety Restrictions and Limitations

Aquaphoril is formally restricted or contraindicated in specific patient populations or conditions as defined in regulatory labeling. These restrictions apply to individuals with severe hepatic impairment (risk of hepatic coma), Anuria (absence of urine production), pre-existing Hypovolaemia (volume depletion), and a known hypersensitivity to the active substance or its sulfonamide derivatives. These constraints establish the necessary limits for the medication's use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Aquaphoril (Xipamide), a high-potency diuretic, is classified in regulatory documentation as a potentially severe medical emergency. The effects are primarily due to an exaggerated therapeutic action, leading to acute fluid and electrolyte imbalances that compromise vital systems.

Documented Overdose Manifestations

Official prescribing information documents overdose presentations related to severe volume depletion and critical electrolyte losses. Clinical manifestations include hypovolaemia (decreased blood volume), resulting in severe dehydration and signs such as orthostatic hypotension. The most serious documented physiological findings are critical hypokalaemia (low potassium) and hyponatraemia (low sodium), which can lead to central nervous system effects like drowsiness and confusion.

Life-Threatening Outcomes and Emergency Actions

Severe electrolyte depletion significantly increases the risk for life-threatening outcomes, specifically cardiac arrhythmias, including the risk of Torsade de pointes, and potential cardiovascular collapse. In patients with pre-existing hepatic impairment, overdose may precipitate hepatic encephalopathy.

Regulators mandate that immediate medical attention must be sought, and emergency services should be contacted at once upon suspicion of an overdose. No specific antidote is known; therefore, treatment is entirely symptomatic and supportive. Required procedural steps include immediate volume replacement, correction of severe electrolyte balance deficits, and continuous Electrocardiogram (ECG) monitoring for cardiac stability.

Therapeutic Uses of Aquaphoril

What Aquaphoril Treats: Main Uses and Benefits

Aquaphoril provides therapeutic support primarily in two distinct domains: managing sustained high arterial pressure (hypertension) and treating symptoms of excessive body fluid accumulation (edema). It is relevant in conditions like heart failure, chronic renal disease, and cirrhosis, where such conditions involve systemic or localized discomfort due to fluid. Its use reduces swelling (edema), particularly in the legs and ankles, and manages internal fluid accumulation like ascites, providing supportive relief that helps ease physical discomfort and assists with maintaining functional stability.


This medication is commonly used to help with symptomatic management in chronic regimens. It is applied in addressing conditions marked by heightened physiological stress, including mild to moderate essential hypertension and fluid retention that manifests as swelling and ascites.

“Aquaphoril is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability.”

By providing the benefit of regulated fluid elimination, the medication helps ease the overall symptom load and contributes to improved day-to-day comfort, which helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Fluid Overload

Aquaphoril supports symptom management by assisting with fluid and systemic blood pressure.

Eligibility and Restrictions for Use

The official regulatory profile for Aquaphoril (Xipamide) strictly defines which populations are eligible for its use. The medicine is authorized for use in adult patients for its approved indications.

Use is absolutely contraindicated in patients with a known hypersensitivity to Xipamide or other sulfonamide-derived drugs. Official labeling prohibits use in critical physiological states, including anuria (absence of urine formation), hepatic pre-coma or coma, and severe electrolyte depletion (e.g., refractory hypokalemia or hyponatremia). Patients with pre-existing gout or Addison's disease are also ineligible.

The medicine is not established or not recommended for pediatric patients. For older adults, caution is required due to an increased risk of electrolyte imbalances. Furthermore, Aquaphoril is contraindicated during pregnancy and the lactation period.

Use requires caution in patients with moderate hepatic impairment and Diabetes Mellitus, as these conditions necessitate close clinical monitoring due to potential complications. Severe renal impairment defines a population for whom use is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Aquaphoril (Xipamide) outlines documented interactions based primarily on pharmacodynamic effects and altered renal clearance. The regulatory text emphasizes specific constraints and required precautions for several drug classes rather than formal absolute contraindications.


Interactions Affecting Drug Exposure

Co-administration with Lithium is documented to lower its renal clearance. This altered elimination leads to increased plasma concentrations of Lithium and an elevated risk of Lithium intoxication. This pharmacokinetic interaction requires adherence to special precautions as detailed in prescribing information. Combination with High-Dose Salicylates may also increase the risk of neurotoxicity.


Pharmacodynamic and Electrolyte-Mediated Risks

The central pharmacodynamic risk is the potential for hypokalemia (low potassium), which may be exacerbated by co-administering with Corticosteroids or certain Laxatives. This electrolyte disturbance is classified as clinically significant because it increases the risk of toxicity from Cardiac Glycosides and raises the danger of severe ventricular arrhythmias, such as Torsades de pointes, when combined with Antiarrhythmic Agents (Class Ia and III) or Phenothiazines.


Functional and Substance Interactions

Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may officially reduce the antihypertensive and diuretic effects of Xipamide. Consumption of Alcohol is documented to increase the overall hypotensive effect. No mandatory time separation rules are explicitly documented for administration.

Mechanism of Action

How Aquaphoril Works


Molecular Blockade in the Distal Tubule

Aquaphoril's mechanism is defined by the direct inhibition of the Sodium-Chloride Symporter (NCC), a specific transport protein in the kidney's distal convoluted tubule. By blocking this transmembrane protein, the active ingredient Xipamide prevents the kidney cells from reabsorbing filtered sodium ( Na^+) and chloride ( Cl^-) back into the bloodstream. . This molecular intervention initiates the primary physiological cascade.


Causal Cascade of Fluid Elimination

The resulting retention of unreabsorbed salt in the tubule creates a strong osmotic gradient, forcing water to remain in the urinary pathway and leading directly to diuresis and the elimination of extracellular fluid volume. This primary action leads to rapid volume contraction, while secondarily resulting in increased potassium loss and reduced calcium excretion due to downstream compensatory mechanisms.


⏱️ Systemic Vascular Modulation

Beyond fluid removal, the long-term, sustained reduction in total body sodium gradually lowers the sodium content within the walls of the peripheral blood vessels. This systemic change reduces the vessels' responsiveness to signals that cause constriction, resulting in modulation of total peripheral resistance over time. This vascular modulation effect is a key, delayed component of the mechanism.

Dosage and Administration Information

How to Use Aquaphoril

The administration of Aquaphoril (Xipamide) is governed by specific protocols, defining the established route, dosing, and timing. As an oral medication, it is available in tablet strengths including 10 mg, 20 mg, and 40 mg. The dosage schedule for both hypertension management and fluid retention is typically based on a once-daily regimen. Standard daily dosing usually ranges from 10 mg to 20 mg, although a higher dose up to 40 mg may be utilized for more pronounced fluid retention. The maximum daily dose stated in prescribing information is 80 mg, which is generally reserved for use under specific conditions, such as higher-grade renal functional impairment.

For proper administration, the tablet must be taken in the morning and specifically after breakfast to align the diuretic effect with waking hours. The tablet is intended to be swallowed whole with sufficient liquid. Certain strengths, such as the 20 mg and 40 mg tablets, are scored, allowing for division where a lower dose is required.

Usage protocols also address specific populations. The medication is not recommended for use in children due to insufficient data on efficacy and safety in that age group. Additionally, the dosage is adjusted in patients with hepatic or renal impairment according to the severity of the functional disorder. For long-term regimens, the dose is gradually tapered off rather than abruptly discontinued.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aquaphoril (Xipamide)

1. Evidence for use in Hypertension (Sustained High Arterial Pressure)

Aquaphoril was studied in populations with high blood pressure (hypertension) primarily through Randomized Controlled Trials (RCTs). Research examined adults with high blood pressure considered mild to moderate, including some patient groups with co-existing conditions like diabetes. The main focus of these studies was to measure changes in blood pressure readings and monitored the duration of changes in blood pressure. Data show patterns related to changes in potassium levels, particularly at higher studied doses. Research provides insight into short-term changes in blood pressure measurements. However, long-term effects are not fully established regarding the prevention of events like strokes, and data on metabolic effects of long-term use are still emerging.

2. Evidence for use in General Fluid Retention (Edema)

Research has explored Aquaphoril in populations experiencing generalized fluid retention (edema). The studies measured outcomes related to systemic or functional imbalance, including the elimination of salt and water (natriuresis and diuresis) and tracked changes in overall body weight. Findings describe patterns observed in the studies related to fluid and salt excretion. Research highlights the measurement of changes in peripheral swelling. Evidence is limited in this area compared to hypertension, as most trials focusing on edema were short-term, and data for certain groups remain insufficient for long-term follow-up.

3. Evidence in Specific Complicated Fluid Conditions

Aquaphoril was evaluated in small patient groups dealing with complex fluid conditions, such as edema related to heart failure, liver cirrhosis, or advanced chronic renal disease. Sample sizes were modest, and the research highlighted the need for individualized assessment of drug disposition in these vulnerable populations. Subgroup findings are uncertain, and certainty remains low for long-term outcomes in these specific cohorts.

4. What is Still Uncertain About Aquaphoril Research

A key limitation is that long-term effects are not fully established regarding the reduction of major cardiovascular events. Evidence quality varies across studies, and for conditions other than hypertension, follow-up durations were limited. Subgroup findings are uncertain due to limited data available for diverse or complex clinical groups.

Frequently Asked Questions (FAQ)

Common questions about Aquaphoril (FAQ)


Q: How long does it typically take for Aquaphoril to start producing noticeable results?

According to official regulatory documents, the diuretic (water loss) effect of Aquaphoril typically begins within one hour of taking the medication. This effect usually reaches its strongest point between the third and sixth hour after administration. Overall, the action of the medication generally lasts for nearly a full day.


Q: Are there any specific foods or beverages known to interact with Aquaphoril?

Official product information states that alcohol consumption can increase the blood pressure-lowering (hypotensive) effect of Aquaphoril. There are no general food or non-alcoholic beverage interactions specifically highlighted in regulatory summaries that are required to be followed.


Q: Can Aquaphoril be taken with over-the-counter pain relievers like ibuprofen or acetaminophen?

Official labeling warns that taking Aquaphoril alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce its ability to lower blood pressure and eliminate fluid. Additionally, co-administration with high-dose salicylates is associated with an increased risk of neurotoxicity (nerve-related side effects).


Q: Are there any known interactions between Aquaphoril and alcohol?

Yes, official regulatory documents state that consuming alcohol can increase the medication's blood pressure-lowering effect. This is classified as a functional interaction.


Q: What is known about the effects of stopping Aquaphoril suddenly?

For individuals on a long-term treatment regimen, official guidance indicates that the prescribed dose is formally described as needing to be gradually tapered off. This requirement for tapering suggests that abrupt discontinuation is not the recommended method for ending treatment.


Q: Does taking Aquaphoril require any specific medical monitoring or routine lab tests?

Official labeling indicates that monitoring is required during treatment due to the risk of changes to the body's fluid and salt levels, known as electrolyte disturbances. Therefore, routine monitoring of blood pressure and blood tests for electrolytes, urea, and creatinine is expected.


Q: How does Aquaphoril potentially affect other chronic health conditions, such as high blood pressure?

Aquaphoril is used to manage high blood pressure and fluid retention. Official labeling indicates that close clinical monitoring is required for patients with existing chronic conditions such as Diabetes Mellitus. Furthermore, the medication is strictly contraindicated (prohibited) for use in patients with severe hepatic impairment, gout, or anuria (absence of urine production).


Q: Does Aquaphoril interact with common non-prescription medications, like cold and flu remedies?

The regulatory label documents that the blood pressure-lowering effect of Aquaphoril can be reduced when taken with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Since NSAIDs are components of some common cold and flu remedies, this potential interaction may be important to be aware of.


Q: Can Aquaphoril be safely split or crushed if swallowing is difficult?

Regulatory information notes that certain tablet strengths are manufactured with a score line, which allows them to be divided for the purpose of a dose reduction if needed. However, official information does not provide instructions regarding whether the tablet can be crushed.


Q: What is the standard duration of treatment described for Aquaphoril in clinical practice?

Aquaphoril is generally described in official product documents as suitable for chronic management regimens. This is because the therapeutic goal is sustained control of fluid and blood pressure dynamics, emphasizing its suitability for long-term use scenarios.


Q: Can taking Aquaphoril be linked to changes in weight?

Studies and official product information indicate that the medication's primary purpose is to help the body eliminate excess salt and water (diuresis). As a result, clinical trials monitored changes in overall body weight as an outcome related to this fluid loss.


Q: What is the general advice if a dose of Aquaphoril is accidentally missed?

General guidance often advises against taking a missed dose if the time is near the next scheduled administration. Instead, the recommendation is typically to resume the regular schedule with the next planned dose.


Q: Can Aquaphoril affect energy levels or cause feelings of tiredness?

Official safety information documents that a common adverse effect is low blood sodium levels, known as hyponatremia. This imbalance can potentially lead to symptoms such as drowsiness or fatigue.


Q: Are there any restrictions regarding driving or operating heavy machinery while taking Aquaphoril?

Due to the medication's mechanism, a common side effect is orthostatic hypotension—a drop in blood pressure when moving to a standing position—which can cause dizziness. For this reason, official documents often include general warnings regarding the performance of tasks that require full mental alertness, such as driving or operating heavy machinery.


Q: Does Aquaphoril cause weight gain or weight loss?

The primary therapeutic effect of the medication is to increase the elimination of water and salt from the body. Consequently, changes in weight are monitored in studies as an outcome directly related to this fluid and volume loss.


Q: What information is available about Aquaphoril use during pregnancy or while breastfeeding?

According to official regulatory documents, Aquaphoril is formally contraindicated (prohibited) for use during both pregnancy and the period of lactation (breastfeeding). This restriction is in place due to the potential for adverse effects on the fetus or the nursing infant.


Q: Is Aquaphoril associated with any known risks to liver or kidney function reported in the literature?

Official documents note that it is strictly contraindicated in cases of severe hepatic impairment (severe liver disease). Furthermore, common effects include temporary increases in serum creatinine and urea, while a serious kidney condition called acute interstitial nephritis is documented as a rare adverse reaction.


Q: What expectations should a patient have regarding follow-up appointments when taking Aquaphoril?

Because routine monitoring for electrolyte disturbances and blood pressure changes is indicated by official labeling during treatment, follow-up appointments that include lab testing are generally expected. These appointments help track the body's response and ensure fluid and salt levels remain balanced.


Q: Can taking Aquaphoril cause skin reactions or rashes?

Yes, official safety information documents the possibility of allergic reactions, which can include the development of a rash. This potential risk is associated with the medication's classification as a sulfonamide derivative.


Q: What is the current safety classification of Aquaphoril by the FDA or EMA?

Regulatory bodies classify Aquaphoril primarily as a thiazide-like diuretic and an antihypertensive agent. This classification places it in the group of medicines used to help the body eliminate excess fluid, and it is listed as a prescription-only medicine.

How should Aquaphoril be stored and disposed of?

How to Store and Dispose of Aquaphoril?

Aquaphoril must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted from 15 C to 30 C (59 F to 86 F). The medication must be protected from moisture and must not be exposed to freezing temperatures or excessive heat.

Keep Aquaphoril in its original packaging and ensure the container is tightly closed. Always store this medicine, and all medicines, out of the sight and reach of children.

For disposal, utilize a medication take-back program if one is available in your area. If a take-back program is unavailable, official guidelines recommend mixing the medicine with an undesirable substance, such as dirt or used coffee grounds, placing the mixture into a sealed bag or container, and discarding it in the household trash. Do not flush Aquaphoril down the toilet unless specifically authorized to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aquaphoril found in:

A-Z Index: